We can’t show the full text here under this license. Use the link below to read it at the source.
Efficacy and safety of cotadutide, a dual glucagon‐like peptide‐1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease
Safety and effectiveness of cotadutide, a drug targeting blood sugar and metabolism, in people with type 2 diabetes and kidney disease
AI simplified
Abstract
Participants receiving cotadutide had a -26.71% reduction in glucose levels compared to a +3.68% increase with placebo.
- Significant improvements in post-meal glucose control were observed with cotadutide, as indicated by the area under the glucose concentration-time curve.
- Continuous glucose monitoring showed that cotadutide users spent 14.79% more time in the target glucose range compared to placebo.
- Cotadutide led to a reduction in body weight by an average of -3.41 kg, while placebo showed minimal weight change.
- In patients with existing kidney issues, cotadutide resulted in a 51% decrease in urinary albumin-to-creatinine ratios, suggesting possible kidney function benefits.
- Mild to moderate adverse events were reported in 71.4% of cotadutide participants compared to 35.0% in the placebo group.
AI simplified
Key numbers
-26.71%
Reduction in Plasma Glucose AUC
Compared to an increase of 3.68% in placebo.
+14.79%
Time in Target Glucose Range Increase
Versus a decrease of 21.23% in placebo.
-3.41 kg
Weight Loss
Compared to a loss of -0.13 kg in placebo.